Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in first-line metastatic pancreatic adenocarcinoma
2015-000905-38Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Ibrutinib + nab-paclitaxel + gemcitabine with Placebo + nab-paclitaxel + gemcitabine (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Aug 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2015-000905-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000905-38.